While the stock market stormed higher Tuesday, a notably large minority of drug companies found themselves in news-specific doldrums. While several fought their way out of negative territory by midday, none was participating in anything near the 4% pop that the broader market enjoyed. Here's the rundown: AstraZeneca ( AZN) said that the FDA has asked for additional information on its cholesterol drug Crestor, a move that would delay the drug's introduction into the U.S. until 2003. The stock was down $1.10, or 3.1%, at $34.50. Forest Laboratories ( FRX) got an approvable letter for its hypertension drug. But the FDA is seeking additional information, which the company expects to provide in the next few months. Its stock was lately off $3.22, or 4.5%, at $68.88. Abbott Laboratories ( ABT) confirmed that it received a letter from the FDA on July 26 that said it did not submit adverse drug reaction reports within the specified 15-day period. The maker of obesity drug Meridia said it plans to correct the problem. After trading down earlier, Abbott was recently up 15 cents, or 0.4%, at $38. Schering-Plough ( SGP) received a downgrade from Merrill Lynch to long-term neutral from strong buy. Merrill cited material issues facing the company. Amid the broader rally, bargain hunters were bidding it up 57 cents, or 2.5%, at $23.08, however. Cephalon ( CEPH) posted a second-quarter profit on higher-than-expected sales Monday evening. But the stock sold off in early morning trading. Some said investors were looking for a bigger earnings-guidance boost as well as better sales of the sleeplessness drug Provigil. Lately, Cephalon was moving higher 96 cents, or 2.2%, at $43.89. Gilead Sciences ( GILD) was halted with news pending. The biotech is hoping for approval of its hepatitis B drug Adefovir. The FDA has asked for information on kidney toxicity for patients with kidney problems.